Syngen Biotech Co., Ltd. Statistics
Syngen Biotech Co., Ltd. (8279) Stock Statistics & Valuation Metrics
Total Valuation
Syngen Biotech Co., Ltd. has a market cap or net worth of TWD 2.21B. The enterprise value is TWD 2.13B.
- Market Cap
- TWD 2.21B
- Enterprise Value
- TWD 2.13B
Share Statistics
Syngen Biotech Co., Ltd. has 27,100,851 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 27,100,851
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Syngen Biotech Co., Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 9.85%.
- Return on Equity (ROE)
- 0.11
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 9.85%
- Return on Capital Employed (ROCE)
- 0.13
- Revenue Per Employee
- 3.86M
- Profits Per Employee
- 490.24K
- Employee Count
- 554
- Asset Turnover
- 0.70
- Inventory Turnover
- 3.91
Valuation Ratios
The current PE Ratio of Syngen Biotech Co., Ltd. is 10.79. Syngen Biotech Co., Ltd.’s PEG ratio is -0.36.
- PE Ratio
- 10.79
- PS Ratio
- 1.08
- PB Ratio
- 0.92
- Price to FCF
- 6.93
- Price to Operating Cash Flow
- 5.50
- PEG Ratio
- -0.36
Income Statement
In the last 12 months, Syngen Biotech Co., Ltd. had revenue of 2.14B and earned 271.59M in profits. Earnings per share was 10.02.
- Revenue
- 2.14B
- Gross Profit
- 723.59M
- Operating Income
- 326.98M
- Pretax Income
- 334.84M
- Net Income
- 271.59M
- EBITDA
- 448.31M
- Earnings Per Share (EPS)
- 10.02
Cash Flow
In the last 12 months, operating cash flow was 401.93M and capital expenditures -82.47M, giving a free cash flow of 319.45M billion.
- Operating Cash Flow
- 401.93M
- Free Cash Flow
- 319.45M
- Free Cash Flow per Share
- 11.81
Dividends & Yields
Syngen Biotech Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 6.12%
- Dividend Per Share
- ―
- Dividend Yield
- 6.12%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 14.43%
- Earnings Yield
- 9.26%
Stock Price Statistics
- Beta
- 0.19
- 52-Week Price Change
- -36.67%
- 50-Day Moving Average
- 79.84
- 200-Day Moving Average
- 92.75
- Relative Strength Index (RSI)
- 47.18
- Average Volume (3m)
- 41.08K
Important Dates
Syngen Biotech Co., Ltd. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Syngen Biotech Co., Ltd. as a current ratio of 2.20, with Debt / Equity ratio of 13.30%
- Current Ratio
- 2.20
- Quick Ratio
- 1.50
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- 0.09
- Interest Coverage Ratio
- 57.84
Taxes
In the past 12 months, Syngen Biotech Co., Ltd. has paid 63.25M in taxes.
- Income Tax
- 63.25M
- Effective Tax Rate
- 0.19
Enterprise Valuation
Syngen Biotech Co., Ltd. EV to EBITDA ratio is 7.29, with an EV/FCF ratio of 6.98.
- EV to Sales
- 1.09
- EV to EBITDA
- 7.29
- EV to Free Cash Flow
- 6.98
- EV to Operating Cash Flow
- 5.55
Balance Sheet
Syngen Biotech Co., Ltd. has TWD 322.49M in cash and marketable securities with TWD 338.68M in debt, giving a net cash position of -TWD 16.19M billion.
- Cash & Marketable Securities
- TWD 322.49M
- Total Debt
- TWD 338.68M
- Net Cash
- -TWD 16.19M
- Net Cash Per Share
- -TWD 0.60
- Tangible Book Value Per Share
- TWD 87.56
Margins
Gross margin is 31.04%, with operating margin of 12.15%, and net profit margin of 10.00%.
- Gross Margin
- 31.04%
- Operating Margin
- 12.15%
- Pretax Margin
- 12.46%
- Net Profit Margin
- 10.00%
- EBITDA Margin
- 14.93%
- EBIT Margin
- 12.15%
Analyst Forecast
The average price target for Syngen Biotech Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -3.92%
- EPS Growth Forecast
- -29.93%
